Moboxen 40 mg Capsule (Mobocertinib)

Moboxen 40 mg is used to treat a certain type of non-small cell lung cancer, especially in adults whose tumors have a genetic mutation known as EGFR exon 20 insertion. These cases tend to be harder to manage with standard chemotherapy.

What is Moboxen 40 mg used for?

It was initially approved by the FDA in 2021 to treat adult patients with non-small cell lung cancer with a specific epidermal growth factor receptor (EGFR) exon 20 insertion mutation, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on the overall response rate and duration of response.

How does Moboxen 40 mg work in non-small cell lung cancer?

Moboxen 40 mg capsule is a targeted cancer medicine that blocks the activity of a protein called EGFR, which helps cancer cells grow and divide. It is designed to specifically target EGFR exon 20 insertion mutations in the EGFR gene that can cause certain types of lung cancer. After taking the medicine, it also produces two active forms in the body that work in a similar way to help stop cancer cell growth.

Mobocertinib Uses and Dosage Information

The recommended dose is 160 mg orally once daily, with or without food. Dose may vary according to the patient’s medical conditions. Take this oral targeted therapy for lung cancer treatment exactly as recommended by your healthcare provider. 

Mobocertinib Side Effects and Important Safety Information

Common Side Effects

Diarrhea (most frequent and potentially severe)

• Nausea 
• vomiting
• Fatigue
• Rash
• Loss of hunger
• Dry skin
• Nail Infection
• Mouth sores

Serious Adverse Reactions

• Abnormal heart rhythm
• ILD (Interstitial lung disease) and Pneumonitis
• Heart toxicity
• Liver toxicity
• Harmful in pregnancy

 Important Safety Information

Knowing safety information is important before taking any medications. Read the safety information below before taking Moboxen Capsule

Warnings and Precautions:

• QT Prolongation: Monitor your heart regularly and avoid using other medications that cause heart failure.
• Interstitial Lung Disease: If ILD or Pneumonitis is confirmed, discontinue permanently.
• Cardiac Effects: Monitor LVEF before and during treatment.
• Severe Diarrhea: If severe diarrhea occurs, consider interruption or reduction in dosage.
• Liver Enzyme Elevation: Monitor liver function tests regularly.
• Reproductive Risk: Use effective contraception, and this treatment is not recommended in pregnancy.

Drug Interactions:

• Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) and inducers.
• Co-administration with QT-prolonging medications increases the risk of arrhythmias.

Use in Specific Populations:

• Pregnancy: Can harm the fetus in the womb.
• Lactation: Though enough evidence is not available, it is not recommended in breastfeeding.
• Pediatric Use: There is no solid evidence of use in children. It is better not to use it in children. 
• Hepatic/Renal Impairment: Use with safety and caution, and regularly monitor with your healthcare provider.

What Research Says: Trial Data at a Glance

The effectiveness of Moboxen 40 mg has been evaluated by the FDA after approval (see the FDA approval information here) of the medication on September 15, 2021, through clinical trials involving patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation. Phase 1/2 clinical trials helped in establishing how well the drug works and how safe it is.

In the trials, it has shown promising results in patients whose cancer has progressed despite previous treatments. Some of the key findings included:

• A notable response rate in patients with metastatic NSCLC carrying the EGFR exon 20 mutation, where the survival rate was increased by a significant percentage.
• Tumor shrinkage was observed in a significant portion of participants who maintained consistency in the treatment and were well monitored by the healthcare giver.
• Improved disease control and fewer side effects compared to what is typically expected with standard chemotherapy.
• A safety profile that was considered manageable with proper monitoring

Based on these results, regulatory authorities in several countries, including EMA (European Medicines Agency), granted accelerated approval, allowing eligible patients earlier access to this targeted therapy.

Though Moboxen isn’t a cure, research shows it may help slow down the disease progression and offer a meaningful clinical benefit to a selected group of patients.

Resources and Help for Patients Starting Treatment

Starting a new cancer treatment is a matter of tension. If you’ve been prescribed Moboxen 40 mg and you do not know how to start, there are helpful resources available to guide you through every step of your treatment journey. Here are a few things you can do that patients often find helpful:

Patient Education

It is essential to understand how this treatment works, what to expect, and how to manage adverse side effects.

Ask your doctor or care team to provide booklets, videos, or websites that explain the treatment in clear and simple language.

Support Programs

Some clinics or pharmaceutical providers offer patient support programs, which may include:

• One-on-one nurse helplines
• Counseling and mental health support
• Reminders for medication and appointments
• Nutritional guidance during treatment

Financial Assistance

If you’re worried about the cost of the treatment, ask your doctor or pharmacist about financial support programs.

In many cases, manufacturers, non-profit organizations, Insurance companies, and the lung cancer support communities offer discounts, co-pay support, or free medication programs for eligible patients.

Community and Peer Support

Talking to others who have already gone through a similar experience can be incredibly helpful. Ask them how they have completed their treatment journey, managed side effects, and overcome all the obstacles. You also might consider joining an online forum, support group, or speaking with a cancer counselor to share concerns and get encouragement.

Frequently Asked Questions about Mobocertinib

Who makes Mobocertinib (Moboxen 40 mg)?

Moboxen 40 mg is developed and manufactured by Everest Pharmaceutical Bangladesh, maintaining all the standards set by the WHO and the FDA. Onus Pharma works as a link between pharmaceuticals and healthcare providers globally, ensuring dexterous distribution and availability of the medication.

How effective is Mobocertinib?

Clinical trials and patient trials have shown that patients who have taken Mobocertinib capsules have a better overall response than their previous targeted therapy. As a targeted therapy, it has shown noticeable outcomes, including objective response, disease control, and long survival rate in the patients. This efficacy makes this treatment different from other NSCLC targeted therapies. Additionally, Mobocertinib holds promise in improving central nervous system efficacy, addressing a significant unmet need in the management of advanced NSCLC with brain metastasis.

How much does Mobocertinib 40 mg tablet cost?

In the UK, mobocertinib (Exkivity) is considered a high-cost targeted therapy, usually accessed through NHS funding or patient-access programs rather than direct purchase. In Bangladesh, Moboxen, the generic version of mobocertinib, is available at a more affordable range through authorized hospital pharmacies, though prices vary depending on manufacturer, dosage strength, and supply source.

How to buy Mobocertinib 40 mg online?

Moboxen 40 mg can be purchased online from licensed pharmacies or authorized medical suppliers. Always verify the pharmacy’s credentials, ensure a valid prescription is required, and confirm product authenticity and shipping regulations before completing the purchase to ensure safe access.

Disclaimer: Information above is not for use as a medical advice alternative; always consult your doctor before taking any prescription medicines.